デフォルト表紙
市場調査レポート
商品コード
1005059

医薬品原薬 (API)の世界市場:タイプ別、合成別、メーカー別、治療用途別の市場調査、予測(~2026年)、COVID-19の累積的な影響

Active Pharmaceutical Ingredients Market Research Report by Type, by Synthesis, by Manufacturer, by Therapeutic Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.01円
医薬品原薬 (API)の世界市場:タイプ別、合成別、メーカー別、治療用途別の市場調査、予測(~2026年)、COVID-19の累積的な影響
出版日: 2021年10月05日
発行: 360iResearch LLP
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医薬品原薬 (API)の市場規模は、2020年の1,886億2,878万米ドルから、2025年末までに2,484億2,070万米ドルに成長すると予想されています。

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮した、COVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

 

当レポートでは医薬品原薬 (API)の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、タイプ・合成・メーカー・治療用途・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査のために考慮された年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画の作成
    • 実行:調査の実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • 市場の見通し
  • メーカーの見通し
  • 治療用途の見通し
  • タイプの見通し
  • 合成の見通し
  • 地域の見通し
  • 競合他社の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズのファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 タイプ別

  • ジェネリック医薬品原薬 (API)
  • 革新的な医薬品原薬 (API)

第7章 合成別

  • バイオテクノロジーの有効成分
  • 合成有効成分

第8章 メーカー別

  • キャプティブAPIメーカー
  • マーチャントAPIメーカー

第9章 治療用途別

  • 心血管疾患
  • 伝染病
  • 糖尿病
  • 腫瘍学
  • 疼痛管理
  • 呼吸器疾患

第10章 南北アメリカ

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第12章 欧州、中東・アフリカ

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第14章 企業のユーザビリティプロファイル

  • Abbvie Inc.
  • API Pharma Tech
  • Astrazeneca
  • Aurobindo Pharma
  • BASF SE
  • BDR Pharmaceuticals Internationals Pvt. Ltd.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Ltd
  • ELI Lilly and Company
  • F. Hoffmann-La Roche
  • Glaxosmithkline PLC
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
  • FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2026
  • FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS, 2018-2026 (USD BILLION)
  • FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS, 2018-2026 (USD BILLION)
  • FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2020 VS 2026 (%)
  • FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2020 VS 2026 (USD BILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2026
  • FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS, 2018-2026 (USD BILLION)
  • FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, 2018-2026 (USD BILLION)
  • FIGURE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2020 VS 2026 (%)
  • FIGURE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2020 VS 2026 (USD BILLION)
  • FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2026
  • FIGURE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CAPTIVE API MANUFACTURERS, 2018-2026 (USD BILLION)
  • FIGURE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CAPTIVE API MANUFACTURERS, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MERCHANT API MANUFACTURERS, 2018-2026 (USD BILLION)
  • FIGURE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MERCHANT API MANUFACTURERS, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2020 VS 2026 (%)
  • FIGURE 26. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2020 VS 2026 (USD BILLION)
  • FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2026
  • FIGURE 28. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 29. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 30. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMMUNICABLE DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 31. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMMUNICABLE DISEASES, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 32. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DIABETES, 2018-2026 (USD BILLION)
  • FIGURE 33. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DIABETES, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 34. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ONCOLOGY, 2018-2026 (USD BILLION)
  • FIGURE 35. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 36. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2026 (USD BILLION)
  • FIGURE 37. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 38. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 39. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 40. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 41. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 42. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 43. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 44. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 45. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 46. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 47. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 48. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 49. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 50. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 51. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 52. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 53. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 54. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 55. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 56. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 57. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 58. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 59. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 60. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 61. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 62. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 63. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 64. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 65. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 66. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 67. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 68. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 69. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 70. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 71. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 72. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
  • TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2026 (USD BILLION)
  • TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2026 (USD BILLION)
  • TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CAPTIVE API MANUFACTURERS, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MERCHANT API MANUFACTURERS, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2026 (USD BILLION)
  • TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMMUNICABLE DISEASES, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DIABETES, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 20. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 21. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 22. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 23. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 24. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 25. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 26. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 27. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 28. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 29. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 30. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 31. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 32. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 33. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 34. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 35. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 36. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 37. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 38. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 39. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 40. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 41. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 42. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 43. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 44. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 45. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 46. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 47. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 48. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 49. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 50. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: SCORES
  • TABLE 51. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BUSINESS STRATEGY
  • TABLE 52. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PRODUCT SATISFACTION
  • TABLE 53. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RANKING
  • TABLE 54. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 55. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: MERGER & ACQUISITION
  • TABLE 56. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 57. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 58. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT & FUNDING
  • TABLE 59. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 60. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: LICENSE & PRICING
目次
Product Code: MRR-430D42AA0F85

The Global Active Pharmaceutical Ingredients Market size was estimated at USD 188.62 billion in 2020 and expected to reach USD 200.25 billion in 2021, at a CAGR 6.49% to reach USD 275.23 billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Active Pharmaceutical Ingredients to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Generic Active Pharmaceutical Ingredients and Innovative Active Pharmaceutical Ingredients.

Based on Synthesis, the market was studied across Biotech Active Pharmaceutical Ingredients and Synthetic Active Pharmaceutical Ingredients.

Based on Manufacturer, the market was studied across Captive API Manufacturers and Merchant API Manufacturers.

Based on Therapeutic Application, the market was studied across Cardiovascular Diseases, Communicable Diseases, Diabetes, Oncology, Pain Management, and Respiratory Diseases.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Active Pharmaceutical Ingredients Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Active Pharmaceutical Ingredients Market, including Abbvie Inc., API Pharma Tech, Astrazeneca, Aurobindo Pharma, BASF SE, BDR Pharmaceuticals Internationals Pvt. Ltd., Boehringer Ingelheim, Bristol-Myers Squibb, Cipla, Inc., Dr. Reddy's Laboratories Ltd, ELI Lilly and Company, F. Hoffmann-La Roche, Glaxosmithkline PLC, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer, Inc., Sanofi, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Active Pharmaceutical Ingredients Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Active Pharmaceutical Ingredients Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Active Pharmaceutical Ingredients Market?
  • 4. What is the competitive strategic window for opportunities in the Global Active Pharmaceutical Ingredients Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Active Pharmaceutical Ingredients Market?
  • 6. What is the market share of the leading vendors in the Global Active Pharmaceutical Ingredients Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Active Pharmaceutical Ingredients Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Define: Research Objective
  • 2.3. Determine: Research Design
  • 2.4. Prepare: Research Instrument
  • 2.5. Collect: Data Source
  • 2.6. Analyze: Data Interpretation
  • 2.7. Formulate: Data Verification
  • 2.8. Publish: Research Report
  • 2.9. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Dynamics

  • 5.1. Introduction
  • 5.2. Drivers
    • 5.2.1. Increasing incidences of chronic diseases
    • 5.2.2. Growing importance of generics coupled with uptakes of biopharmaceuticals
    • 5.2.3. Technological advancements in active pharmaceutical ingredients
    • 5.2.4. Adoption of AI-based tools and organ-on-chip models in drug discovery & development
    • 5.2.5. Rising focus on precision medicine and growing investment
  • 5.3. Restraints
    • 5.3.1. Unsupportive price control policies for drug across various countries
    • 5.3.2. Increasing availability of counterfeit drugs
  • 5.4. Opportunities
    • 5.4.1. Emergence of biosimilars
    • 5.4.2. Highly effective active pharmaceutical ingredients
  • 5.5. Challenges
    • 5.5.1. High cost associated with the manufacturing process
    • 5.5.2. Concern associated with the product differentiation

6. Active Pharmaceutical Ingredients Market, by Type

  • 6.1. Introduction
  • 6.2. Generic Active Pharmaceutical Ingredients
  • 6.3. Innovative Active Pharmaceutical Ingredients

7. Active Pharmaceutical Ingredients Market, by Synthesis

  • 7.1. Introduction
  • 7.2. Biotech Active Pharmaceutical Ingredients
  • 7.3. Synthetic Active Pharmaceutical Ingredients

8. Active Pharmaceutical Ingredients Market, by Manufacturer

  • 8.1. Introduction
  • 8.2. Captive API Manufacturers
  • 8.3. Merchant API Manufacturers

9. Active Pharmaceutical Ingredients Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Communicable Diseases
  • 9.4. Diabetes
  • 9.5. Oncology
  • 9.6. Pain Management
  • 9.7. Respiratory Diseases

10. Americas Active Pharmaceutical Ingredients Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Active Pharmaceutical Ingredients Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand

12. Europe, Middle East & Africa Active Pharmaceutical Ingredients Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Key Player
  • 13.4. Competitive Scenario
    • 13.4.1. Merger & Acquisition
    • 13.4.2. Agreement, Collaboration, & Partnership
    • 13.4.3. New Product Launch & Enhancement
    • 13.4.4. Investment & Funding
    • 13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. Abbvie Inc.
  • 14.2. API Pharma Tech
  • 14.3. Astrazeneca
  • 14.4. Aurobindo Pharma
  • 14.5. BASF SE
  • 14.6. BDR Pharmaceuticals Internationals Pvt. Ltd.
  • 14.7. Boehringer Ingelheim
  • 14.8. Bristol-Myers Squibb
  • 14.9. Cipla, Inc.
  • 14.10. Dr. Reddy's Laboratories Ltd
  • 14.11. ELI Lilly and Company
  • 14.12. F. Hoffmann-La Roche
  • 14.13. Glaxosmithkline PLC
  • 14.14. Merck & Co., Inc.
  • 14.15. Mylan N.V.
  • 14.16. Novartis AG
  • 14.17. Pfizer, Inc.
  • 14.18. Sanofi
  • 14.19. Sun Pharmaceutical Industries Ltd
  • 14.20. Teva Pharmaceutical Industries Ltd

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing